2027 Speakers

Rick Aldridge, MBChB

Managing Director

BMO Capital

Hillary Andrews, PhD

Sr Director, Science Policy & Strategy

Friends of Cancer Research (FOCR)

Roy Baynes, PhD

EVP and CMO

Eikon Therapeutics

David Berman MD, PhD

Chief Development Officer

Moderna Therapeutics

Chantal Bernatchez, PhD

Sr Director, CTMC; Associate Director, Cell Therapy Process Development

MD Anderson Cancer Center

Gwendolyn Binder, PhD

President, Science & Technology

Cabaletta Bio

Jeffrey Bockman, PhD

Expert Advisor and EVP, Oncology

Lumanity

Lisa Butterfield, PhD

Cancer Vaccines & Immunotherapy Expert

Alexander Cao, PhD

Executive Director, Head of Translational Clinical Biomarkers

Merck

Daniel S. Chen, MD, Phd

Founder and CEO

Synthetic Design Lab, Inc

Charles Drake, MD, PhD

VP, Immno-Oncology

J&J Innovative Medicine

Michael Dustin, PhD

Director of Research / Professor, Molecular Immunology

Kennedy Institute of Rheumatology / University of Oxford

Arnab Ghosh, MBBS, PhD

Sr Medical Director

J&J Innovative Medicine

Stephanie Goff, MD, FACS, FSSO

Director, CCR Surgical Oncology Services; Senior Research Physician

National Cancer Institute, NIH

Asthika Goonewardene, MBA

Senior Managing Director, Senior Biotech Analyst

Leerink Partners

Dierderik Grootendorst, PhD

Director, Global Oncology Imaging

BMS

James Gulley, MD, PhD, FACP

Co-Director, Center for Immuno-Oncology, CCR & Clinical Director

National Cancer Institute, NIH

Parameswaran Hari, MD

CMO

Obsidian Therapeutics

Priti Hegde, PhD

SVP & Global Head, Research

Kite Pharma

Axel Hoos, MD, PhD

former CEO

Scorpion Therapeutics

Albert Hwang, MD, MBA

Managing Director ; Head of US Healthcare Investment Banking

Morgan Stanley

Shweta Jain

VP, Head of Early Development, Oncology Clinical Development

Merck

Michael Kalos, PhD

Managing Director

Next Pillar Consulting

Howard Kaufmann, MD, FACS

President and CEO

Ankyra Therapeutics

Rajiv Kaul

Portfolio Manager, Equity Division

Fidelity Investments

Ashley Koegel, MD

Global Program Lead for Hematology, Oncology & Cell Therapy

BMS

David Leung, MD, PhD

Head of Imaging

Daiichi Sankyo

Pending: Feng Li, PhD

Chairman of the Board, CEO/General Manager

Mabworks

Jason Luke, MD, FACP, FASCO

CMO

Strand Therapeutics

Julie Martin

President & CEO

Scimega

Lei Meng, MBA

Managing Director, Life Sciences

Jennifer Michaelson, Ph.D.

Chief Scientific Officer

Cullinan Therapeutics

Alex Miller, PhD

Sr Associate, Venture

RA Capital Management

PK Morrow, MD

Head, Oncology Therapuetic Area Unit

Takeda

Jayant Narang, MD

Sr Medical Director, Clinical Oncology Imaging Lead, Preclinical and Translational Sciences

Takeda Pharmaceuticals

Pamela Ohashi, PhD, FRSC

Senior Scientist & Director, Tumor Immunotherapy Program

Princess Margaret Cancer Center / University of Toronto

John Pagel, MD, PhD

SVP, Clinical Development, Global Head Medical Oncology, Hematology

Eli Lilly and Co

Carol Pena, PhD

AVP, CDx Development, Translational Oncology

Merck

Robert Pierce, MD

CSO

Ernexa Therapeutics

Ellen Puré, AB, PhD

Professor, Department of Biomedical Sciences & Director, Penn Vet Cancer Center

University of Pennsylvania

Koustubh Ranada, PhD

SVP, Translational Medicine

Immunocore

Naiyer Rizvi, MD

CMO

Synthekine

Alexander "Sasha" Rudensky, PhD

Chair, Immunology Program and Director, Ludwig Center

Memorial Sloan Kettering Cancer Center

Angus Sinclair, PhD

CSO

LabGenius Therapeutics

Zhen Su, MD, MBA

CEO

Morengo Therapeutics

Peter Paul Tak, MD, PhD

President and CEO

Candel Therapeutics

Sarah Warren, PhD

Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation

Kite Pharma / Gilead Sciences

Laurence Zitvogel, MD, PhD

Scientific Director

Gustave Roussy Cancer Center